A precision cannabis inhaler allowed hospitalized patients to use far less cannabis while achieving pain relief
Hospitalized patients using a metered-dose cannabis inhaler consumed about 95% less cannabis than their pre-hospitalization amounts while reporting significant pain reduction and high satisfaction.
Quick Facts
What This Study Found
Daily cannabis consumption dropped from a median of 1,000 mg to 51 mg when using the SYQE Inhaler. Pain intensity fell from a median of 7 to 4 (out of 10) within 30-60 minutes of inhalation. Patient satisfaction was rated 6 out of 7. Only mild cough was reported as an adverse event in 3 participants.
Key Numbers
Median daily dose: 51 mg (range 20-96) vs. 1,000 mg pre-hospitalization (range 660-3,300). Pain: 7 to 4 on a 0-10 scale. Satisfaction: 6/7. Hospital stay: median 5 days (range 3-7). 3 patients had mild cough.
How They Did This
Pilot open-label study of the SYQE Inhaler in hospitalized medical cannabis patients. Each dose delivered 500 micrograms THC from 16 mg cannabis. Patients received up to 4 scheduled and 4 as-needed doses daily. Pain, nausea, and satisfaction were assessed by questionnaire.
Why This Research Matters
Cannabis by combustion is not feasible in hospitals. A precision inhaler that delivers consistent microdoses could make medical cannabis accessible to hospitalized patients while dramatically reducing the amount consumed.
The Bigger Picture
Precision dosing technology could bridge the gap between the uncontrolled dosing of traditional cannabis consumption and the pharmaceutical standards expected in hospital settings.
What This Study Doesn't Tell Us
Pilot study with no control group. Small sample size (not specified in abstract). Open-label design and self-reported outcomes. Patients were already experienced cannabis users, so results may not generalize to cannabis-naive patients.
Questions This Raises
- ?Would cannabis-naive patients respond similarly to microdosed THC?
- ?Could this device replace opioids for certain types of hospital pain management?
- ?What is the minimum effective THC dose for different pain conditions?
Trust & Context
- Key Stat:
- 95% reduction in daily cannabis consumption with precision inhaler
- Evidence Grade:
- Small pilot study without controls. Promising feasibility data but no comparator group to assess placebo effect.
- Study Age:
- 2020 pilot study. Demonstrates feasibility of precision cannabis dosing in hospital settings.
- Original Title:
- Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study.
- Published In:
- Palliative & supportive care, 18(1), 12-17 (2020)
- Authors:
- Vulfsons, Simon(2), Ognitz, Miriam, Bar-Sela, Gil(5), Raz-Pasteur, Ayelet, Eisenberg, Elon
- Database ID:
- RTHC-02900
Evidence Hierarchy
A small preliminary study to test whether a larger study is feasible.
What do these levels mean? →Frequently Asked Questions
How much THC was in each dose?
Each inhalation delivered 500 micrograms of THC from 16 mg of cannabis flower, a precisely metered microdose far smaller than typical cannabis consumption.
Why can't patients smoke cannabis in the hospital?
Hospital fire safety, smoke exposure to other patients and staff, and the inability to control dosing through combustion make traditional cannabis smoking infeasible in clinical settings.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02900APA
Vulfsons, Simon; Ognitz, Miriam; Bar-Sela, Gil; Raz-Pasteur, Ayelet; Eisenberg, Elon. (2020). Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study.. Palliative & supportive care, 18(1), 12-17. https://doi.org/10.1017/S147895151900021X
MLA
Vulfsons, Simon, et al. "Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study.." Palliative & supportive care, 2020. https://doi.org/10.1017/S147895151900021X
RethinkTHC
RethinkTHC Research Database. "Cannabis treatment in hospitalized patients using the SYQE i..." RTHC-02900. Retrieved from https://rethinkthc.com/research/vulfsons-2020-cannabis-treatment-in-hospitalized
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.